During protein electrophoresis, α1-AT is located within the α1-globulin band. α1-AT is a liver-synthesized glycoprotein with a half-life of about 4-5 days. There are substances in the serum that inhibit trypsin activity, of which α1-AT accounts for 90%. In addition to inhibiting trypsin activity, α1-AT can also inhibit chymotrypsin, factor XII auxiliary factor, and neutrophil elastase. α1-AT exists in tears, duodenal juice, saliva, nasal secretions, cerebrospinal fluid, lung secretions, and breast milk. The concentration of α1-AT in amniotic fluid is equivalent to 10% of serum. Inflammation, tumor, pregnancy, or estrogen therapy can increase the concentration of α1-AT in serum by 2-3 times, but these stimuli are almost ineffective for patients with α1-AT deficiency.
In the normal human body, there are exogenous and endogenous proteases, such as bacterial toxins and proteases released from leukocyte lysis, which have destructive effects on the liver and other organs. α1-AT can antagonize these enzymes to maintain the integrity of tissue cells. When α1-AT is deficient, these enzymes can erode liver cells, especially in newborns whose intestinal cavity digestion and absorption function is not完善, more macromolecular substances enter the blood, and the liver of infants with α1-AT deficiency is more susceptible to damage. In addition, α1-AT also has the function of regulating immune responses, affecting the clearance of antigen-antibody immune complexes, complement activation, and inflammation. It can also inhibit platelet aggregation and the occurrence of fibrinolysis. When α1-AT is deficient, the mechanism of body balance mentioned above is dysregulated, leading to tissue damage.
The pathological feature of the liver is that there are round or oval deposits in the liver cells around the lobules, with a diameter of 1-40μm. These spherical particles increase in size with age and are more easily seen as the infant matures. HE staining shows eosinophilic staining in the cytoplasm of liver cells, and PAS staining is most clearly resolved after treatment with amylase.
Immunofluorescence and immunocytochemistry show that the inclusions are α1-AT, and these inclusions can also be seen in heterozygotes. The density and extent of these inclusions seem to have no definite relationship with the presence or absence of liver disease, but the absence of these inclusions indicates no occurrence of liver disease, suggesting that these inclusions may play a certain role in the pathogenesis of the disease.
Under the electron microscope, it can be seen that the rough endoplasmic reticulum within the liver cells is expanded and contains characteristic deposits of varying morphologies, while no such deposits are found in the Golgi apparatus. The amount of deposits varies greatly among individuals, and they can also be seen in bile duct cells. In addition, glycogen, vacuoles, lipofuscin, and bile stasis can also be seen in the liver cells.
Newborns with Pizz phenotype, if accompanied by cholestatic jaundice due to α1-AT deficiency, the liver shows the following three pathological manifestations:
One: Liver cell injury
The characteristics are the enlargement of liver cells, relatively mild inflammatory cell infiltration, and mostly mononuclear cell infiltration. It can be accompanied by or without liver fibrosis, and there may be cholestasis, but no bile thrombus formation in the portal area.
Two: Portal fibrosis of the liver and bile duct hyperplasia
There is extensive portal area fibrosis, even with manifestations similar to liver cirrhosis, with obvious bile duct hyperplasia. Jaundice regressed 6 months ago, but the liver and spleen have progressively enlarged and hardened. There have been two cases of portal hypertension, but there is no abnormality in the extrahepatic bile ducts in such patients.
3. Maldevelopment of small bile ducts
The liver structure is normal, with slight liver cell damage, only slight fibrosis at the portal area, but the number of bile ducts is significantly reduced, bile stasis is scattered within the liver lobules, and the clinical course is progressive jaundice, accompanied by itching and hypercholesterolemia.